Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RVTY | US
-0.38
-0.44%
Healthcare
Diagnostics & Research
30/06/2024
24/04/2026
86.77
87.27
87.56
85.59
Revvity Inc. provides products services and solutions to the diagnostics life sciences and applied services markets worldwide. It operates through two segments Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments reagents informatics software subscriptions detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market as well as contract research and laboratory services. It also provides analytical technologies solutions and services for its customers to understand the characterize the health of various aspects including air water and soil. In addition this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market which includes the chemical semiconductor and electronics energy lubricant petrochemical and polymer industries. The Diagnostics segment provides instruments reagents assay platforms and software products for the early detection of genetic disorders such as pregnancy and early childhood as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities disorders and diseases including down syndrome hypothyroidism muscular dystrophy infertility and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology immunodiagnostics and drug discovery. It serves pharmaceutical and biotechnology companies laboratories academic and research institutions public health authorities private healthcare organizations doctors and government agencies. The company was formerly known as PerkinElmer Inc. and changed its name to Revvity Inc. in April 2023. Revvity Inc. was founded in 1937 and is headquartered in Waltham Massachusetts.
View LessLargecap (10B - 200B USD)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
Weak P/E, and PEG ratio indicator
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
52.5%1 month
42.2%3 months
39.4%6 months
37.6%74.79
23.04
1.88
0.51
0.30
22.97
6.20
3.03
781.42M
10.70B
10.70B
0.23
15.05
58.00
-2.50
2.51
6.53
4.83
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
14.28
Range1M
14.28
Range3M
35.42
Rel. volume
1.18
Price X volume
94.53M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Guardant Health Inc | GH | Diagnostics & Research | 88.91 | 10.94B | 1.18% | n/a | -83144.02% |
| Charles River Laboratories International Inc | CRL | Diagnostics & Research | 169.8 | 8.77B | 1.23% | 23.63 | 76.32% |
| QIAGEN N.V | QGEN | Diagnostics & Research | 38.41 | 8.54B | 1.16% | 122.86 | 41.16% |
| ICON Public Limited Company | ICLR | Diagnostics & Research | 102.17 | 8.46B | -3.92% | 34.54 | 37.38% |
| Bio-Rad Laboratories Inc | BIO | Diagnostics & Research | 287.84 | 7.97B | 2.28% | n/a | 20.54% |
| Lantheus Holdings Inc | LNTH | Diagnostics & Research | 84.33 | 5.86B | 1.82% | 19.19 | 60.42% |
| Bruker Corporation | BRKR | Diagnostics & Research | 36.55 | 5.53B | 0.91% | 26.13 | 126.86% |
| Celcuity Inc | CELC | Diagnostics & Research | 121.03 | 4.48B | 6.58% | n/a | 54.62% |
| Sotera Health Company | SHC | Diagnostics & Research | 15.58 | 4.41B | 1.63% | 114.29 | 555.18% |
| RadNet Inc | RDNT | Diagnostics & Research | 57.63 | 4.26B | 2.11% | 378.67 | 195.04% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Dolby Laboratories Inc | DLB | Media - Diversified | 64.08 | 6.11B | 1.78% | 34.32 | 0.00% |
| FBIN | FBIN | Building Products & Equipment | 41.54 | 5.16B | 0.34% | 25.57 | 130.24% |
| Thor Industries Inc | THO | Recreational Vehicles | 79 | 4.18B | 0.24% | 23.44 | 27.88% |
| Cinemark Holdings Inc | CNK | Media - Diversified | 28.48 | 3.49B | -0.42% | 27.93 | 934.91% |
| VeriFone Systems Inc | PAY | Building Products & Equipment | 27.25 | 3.39B | 0.96% | 102.46 | 2.10% |
| Polaris Industries Inc | PII | Recreational Vehicles | 60.04 | 3.35B | 1.06% | 14.48 | 170.51% |
| LCI Industries | LCII | Recreational Vehicles | 120.01 | 3.06B | -0.45% | 25.82 | 77.66% |
| Harley-Davidson Inc | HOG | Recreational Vehicles | 23.11 | 3.04B | -1.15% | 7.33 | 218.58% |
| Pitney Bowes Inc | PBI | Building Products & Equipment | 15.58 | 2.80B | 1.37% | n/a | -571.93% |
| IMAX Corporation | IMAX | Media - Diversified | 36.45 | 1.92B | -0.44% | 54.26 | 110.44% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 22.97 | 12.67 | Expensive |
| Ent. to Revenue | 6.20 | 44.00 | Cheaper |
| PE Ratio | 74.79 | 40.09 | Expensive |
| Price to Book | 1.88 | 77.50 | Cheaper |
| Dividend Yield | 0.23 | 1.18 | Poor |
| Std. Deviation (3M) | 39.39 | 59.59 | Lower Risk |
| Debt to Equity | 0.51 | -14.36 | Expensive |
| Debt to Assets | 0.30 | 0.34 | Par |
| Market Cap | 10.70B | 13.71B | Emerging |